Regeneron with its Partner NIAID Report the Initiation of P-III Trial to Evaluate REGN-COV2 for Treatment and Prevention of COVID-19
Shots:
- The P-III trial involves assessing REGN-COV2 with an expected enrollment of 2000 patients at 100 sites which will be evaluated to prevent infection among uninfected people who have had close exposure to a COVID-19 patient
- REGN-COV2 is also being evaluated in P-II/III portion of two P-I/II/III trials testing the cocktail's ability to treat hospitalized (N= 1-850) and non-hospitalized (N=1050) patients with COVID-19 across 150 sites in the US- Brazil- Mexico- and Chile with expected results in late summer. Additionally- clinical progress follows positive recommendations from IDMC of P-I trial which involved assessing of REGN-COV2 in 30 hospitalized and non-hospitalized patients with COVID-19
- REGN-COV2 is double-antibody cocktail developed using VelociMab and manufacturing capabilities for the prevention and treatment of COVID-19
Click here to read full press release/ article | Ref: PRNewswire | Image: Behance
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
